{
    "Trade/Device Name(s)": [
        "Diazyme 1,5-AG Assay"
    ],
    "Submitter Information": "Diazyme Laboratories Inc.",
    "510(k) Number": "K180209",
    "Predicate Device Reference 510(k) Number(s)": [
        "K031604"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NOZ"
    ],
    "Summary Letter Date": "August 23, 2018",
    "Summary Letter Received Date": "August 24, 2018",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 864.7470"
    ],
    "Regulation Name(s)": [
        "Glycosylated hemoglobin assay"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "1,5-anhydroglucitol"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Beckman AU680"
    ],
    "Method(s)/Technology(ies)": [
        "Enzymatic colorimetric assay"
    ],
    "Methodologies": [
        "Enzymatic quantitation using pyranose oxidase, colorimetry with peroxidase, glucose removal via hexokinase and pyruvate kinase pretreatment"
    ],
    "Submission Type(s)": [
        "Assay",
        "Kit",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for Diazyme 1,5-AG enzymatic assay for quantitation of 1,5-anhydroglucitol in serum and plasma to monitor glycemic control in diabetes",
    "Indications for Use Summary": "Intended for quantitative determination of 1,5-anhydroglucitol in serum or plasma for intermediate term (1-2 weeks) glycemic control monitoring in people with diabetes; for in vitro diagnostic use only",
    "fda_folder": "Hematology"
}